Clinical Trials Logo

Clinical Trial Summary

Objectives: To perform pilot study using unilateral transcutaneous electrical stimulation (TENS) on thegenital nerves (dorsal nerve penis and cavernous nerves) for improving of the intracorpereal pressure and full penil erection in men after exclusion neurogenic, endrogenic and earteriogenic disorders. The investigators hypothesize that this therapy will be effective at improving erectile dysfunction (ED). Material and methods: The study will comprised 20 patients with ED randomized in two groups. Two adhesive skin electrodes are placed, one at the root of the penis and near the pubic symphysis as a cathode, and a second 2-3cm lateral to the penis. Stimulation is delivered for 30 min at the maximal tolerable stimulation amplitude at 210μs pulse width and in one group with a pulse rate at 20Hz, the second group at 60Hz. The penile tumescence and rigidity observed during stimulation are recorded in both groups of patients. Erection Harness Score (EHS) and Quality of Erection Questionnaire (QEQ) are assessed at baseline, immediately after stimulation and 2 weeks after stimulation.


Clinical Trial Description

The study is a randomized prospective unblended study. 20 male patients with ED participated to the study. Vulnerable patients, patients with a pacemaker, patients with genital lesions, previous pudendal nerve or genital surgeries, vascular disease or neurological disorders are excluded. Due to the risk of iatrogenic lesions of the erectile nerves, patients suffering from ED secondary to radical prostatectomy are not prime candidates for such a study, however due to the incidence of this etiology and the important impact in the general male population, the investigators decided to include these patients in participants study. The assessment at baseline consistes of a medical history, a neuropelveological workup of the pelvic somatic nerves, pudendal ultrasonography with doppler. Stimulation is performed using a battery powered handled stimulator (N602-1C TENS Elektrostimulator - CH). Monophasic square constant current pulse with a pulse duration of 210 μs. The patients are randomized into two separate groups, a group A with fixed stimulation at 20Hz, a group B with fixed stimulation at 60Hz. Because both genital nerves are located just few millimeters below the skin, stimulation can be achieved using two adhesive skin surface electrodes (diameter 32mm, PALS Platinum, Axelgaard, Lystrup, Denmark), one placed at the root of the penis and in vicinity of the symphysis pubis as a cathode, and a second 2-3cm lateral to the penis. Precautions are taken to ensure good contact between skin and the electrodes, including removal of hairs. Furthermore, the patients are instructed to place the electrodes correctly and to clean the skin before application of the electrodes. The patients are encouraged to set the amplitude as high as tolerable each time when stimulating at home. Because the different genital nerves may react to different frequency of stimulation , stimulation is delivered for 30 min at the maximal tolerable stimulation amplitude at 210μs pulse width with a pulse rate at 20Hz in patients group A, and at 60Hz in patients group B. The first transcutaneous stimulation is performed in the presence of MP: The penile tumescence and rigidity observed during stimulation are recorded in both groups of patients. Then stimulation is performed at home at least twice daily for 15 min in each session for a period of 2 weeks. The patients recorde the stimulation amplitude after each session. Erection Harness Score (EHS) and Quality of Erection Questionnaire (QEQ) are assessed for 2 weeks before stimulation, during the 2 weeks of stimulation, and for 2 weeks after the final stimulation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05231083
Study type Interventional
Source Possover International Medical Center AG
Contact Marc Possover, PhD
Phone +41797507995
Email m.possover@possover.com
Status Not yet recruiting
Phase N/A
Start date February 1, 2025
Completion date September 1, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05366504 - LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment Phase 2/Phase 3
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Recruiting NCT02573805 - the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males N/A
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Recruiting NCT02225548 - Sagene 2014 - Parkinson's Disease and Erectile Dysfunction Phase 4
Completed NCT02587988 - Trial to Evaluate the Efficacy and Safety of HCP1302 Phase 3
Completed NCT02945462 - Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED) Phase 1
Completed NCT01937871 - A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) Phase 3
Completed NCT01698684 - Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction Phase 4
Not yet recruiting NCT01321489 - A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies Phase 3
Terminated NCT01262833 - Pudendal Assessment in Erectile Dysfunction N/A
Completed NCT02226237 - Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy N/A
Completed NCT01230541 - Effect of Udenafil on Spermatogenesis Phase 1
Completed NCT01037218 - Treatment of Erectile Dysfunction II Phase 3
Completed NCT01037244 - Treatment of Erectile Dysfunction I Phase 3
Recruiting NCT00313898 - Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males Phase 4
Completed NCT00667979 - Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse Phase 4
Completed NCT00663728 - Assessment of Duration of Erection With Vardenafil 10 mg Phase 4
Completed NCT00421083 - Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury Phase 3